Two groups have recently proposed that type II anti-CD20 monoclonal antibodies (mAbs) B1 (tositumomab) and GA101, as well as anti-HLA-DR antibody (L243), induce strong homotypic adhesion and direct cell death. They claim, on the basis of annexin V, propidium iodide (PI), and flow cytometric analysis, that up to 80% of cell death occurs after 24 hours of treatment with these mAbs. [1] [2] [3] We have also observed, after treatment of B lymphoma cells in vitro with either anti-HLA-DR BK267 or anti-CD20 antibody B1 (BioGenex), an apparent 30% to 70% increase in cell death of different human B lymphoma cell lines by fluorescence-activated cell sorting (FACS) analysis of either 7-AAD-stained cells ( Figure  1A and data not shown). However, in parallel observations in Bürker chambers, we found that only 5% of antibody-treated cells were stained with Trypan blue and most appeared alive (data not shown). We then observed in alamarBlue vital dye (AbD Serotec) assays that only 2% to 12% cell death could be measured after 24 hours of treatment of the same cell lines with anti-HLA-DR or B1 antibody ( Figure 1B and data not shown). Seeing that the cells formed large and tight aggregates in the presence of the antibodies, which were resistant to vigorous pipetting, we thought that this aggregation could have significantly altered the flow cytometric data. We therefore performed cytospins of cells treated with mAbs and stained with 7-AAD and DAPI. Counting 7-AAD ϩ cells in cytospins showed very low mortality, with about 5% increased dead cells in antibody compared with controls ( Figure 1C) . This was markedly different from parallel flow cytometry ( Figure 1A ). Indeed, with Raji cells, 83% and 48.6% 7-AAD ϩ cells were revealed by FACS analysis after HLA-DR and B1 treatment, respectively, compared with only 7% in cytospins ( Figure 1A ,C). As positive control, B-CLL treated with alemtuzumab and human Figure 1C) , consistent with the results obtained by FACS. 4 We conclude that flow cytometry results with anti-HLA-DR or type II anti-CD20 antibodies are largely due to cell aggregation. Large aggregates containing 30 to 100 cells are probably mostly excluded from the analysis, falling outside the gate of scatter plots. Dead cells are in contrast enriched within the single-cell population because aggregation is an energy-dependent process. An apparent rapid loss of cells due to aggregation was confirmed in flow cytometry by counting the absolute number of events using calibrated beads. Indeed, 87% and 70% apparent decrease in total cell number was observed at 24 hours in anti-HLA-DR-and B1-treated samples, respectively ( Figure 1D) .
Altogether, these observations suggest that FACS analysis should be interpreted with caution in the functional study of antibodies that cause strong homotypic adhesion, unless means are found to disaggregate cells without causing cell death. They also suggest that anti-HLA-DR and anti-CD20 B1 antibody may induce much less direct cell death than previously suggested and the reason for their efficacy in vivo may reside in other properties, such as homotypic adhesion itself inducing opsonization or immune mediated mechanisms, as recently suggested for type II anti-CD20 mAbs. 5 
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Novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates
Golay et al raise several important points regarding the possible pitfalls in assessing cell death by flow cytometry. In particular, they refer to experiments on anti-CD20 and HLA-DR monoclonal antibodies (mAbs) reported by our groups in the past year. 1,2 We fully concur that more than one technique should be performed to validate any cell death phenomenon and that flow cytometry alone is insufficient. For exactly these reasons we performed real-time and snapshot light microscopic analysis, electron microscopic, and growth inhibition assays to demonstrate by 4 different techniques that type II anti-CD20 and HLA-DR mAbs elicit a novel form of lysosomal-dependent death related to homotypic adhesion (HA) and that type I anti-CD20 mAbs do not. The central argument presented by Golay et al is that cells undergoing HA become sensitive to pipetting and flow cytometric analysis, although it is unclear as to why this should be the case. Nevertheless, we reported in situ experiments with SYTOX green (Invitrogen) that excluded flow cytometry and pipetting. Importantly in these experiments, where there was no mechanical disruption, HA was accompanied by increased SYTOX green positivity, indicative of cell death ( Figure 1A and Ivanov et al 1 ). We also reported a clear and substantial decrease in viable cell proliferation in the presence of tositumomab or HLA-DR mAb, using XTT assays ( Figure 1B and Ivanov et al 1 ). This assay again excludes the mechanical issues of pipetting and flow cytometry detailed by Golay et al. Both the XTT reagent used by us and the alamarBlue used by Golay et al operate through a common mechanism (reduction by metabolically active cells to give a color change). Therefore, the differences observed between our groups are hard to reconcile, but may potentially be explained by differences in cell density or dye incubation time used. Furthermore, we have previously confirmed that the loss of cell viability observed translated into a loss of clonogenic survival. 3 Although HA correlates with cell death, the relationship is not direct for all mAbs. For example, the pan-HLA mAb A9-1 caused high levels of aggregation yet elicited relatively low levels of cell death compared with anti-HLA DR and type II anti-CD20 mAbs. 1 This lack of a direct relationship implies that mechanisms other
